Alfred Fahr

Alfred Fahr

Auto-generated profile, based on publicly available information

Alfred Fahr

Department of Pharmaceutical Technology, Friedrich-Schiller-University Jena, Lessingstrasse 8, 07743 Jena, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
AFAlfred Fahr
Alfred Fahr
XLXiangli Liu
Xiangli Liu
The drug candidates coming from combinatorial chemistry research and/or the drugs selected from biologically based high-throughput screening are quite often very lipophilic, as these drug candidates exert their pharmacological action at or in biological membranes or membrane-associated proteins. This challenges drug delivery institutions in industry or academia to develop carrier systems for the optimal oral and parenteral administration of these drugs. To mention only a few of the challenges for this class of drugs: their oral bioavailability is poor and highly variable, and carrier development for parenteral administration is faced with problems, including the massive use of surface-active excipients for solubilisation. Formulation specialists are confronted with an even higher level of difficulties when these drugs have to be delivered site specifically. This article addresses the emerging formulation designs for delivering of poorly water-soluble drugs.

1 November 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AFAlfred Fahr
Alfred Fahr
PHPeter van Hoogevest
Peter van Hoogevest
SMSylvio May
Sylvio May
NBNill Bergstrand
Nill Bergstrand
MLMathew L. S. Leigh
Mathew L. S. Leigh

1 November 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
MAMukul Ashtikar
Mukul Ashtikar
KNKalpa Nagarsekar
Kalpa Nagarsekar
AFAlfred Fahr
Alfred Fahr

11 August 2011 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
PHPeter van Hoogevest
Peter van Hoogevest
XLXiangli Liu
Xiangli Liu
AFAlfred Fahr
Alfred Fahr
Introduction: For poorly soluble compounds, a good bioavailability is typically needed to assess the therapeutic index and the suitability of the compound for technical development. In industry, the selection of the delivery technology is not only driven by technical targets, but also by constraints, such as production costs, time required for development and the intellectual property situation. Areas covered: This review covers current developments in parenteral and oral delivery technologies and products for poorly water-soluble compounds, such as nano-suspensions, solid dispersions and liposomes. In addition, the use of biorelevant dissolution media to assess dissolution and solubility properties is described. Suggestions are also included to systematically address development hurdles typical of poorly water-soluble compounds intended for parenteral or oral administration. Expert opinion: A holistic assessment is recommended to select the appropriate delivery technology by taking into account technical as well as intellectual property considerations. Therefore, first and foremost, a comprehensive physico-chemical characterization of poorly water-soluble compounds can provide the key for a successful selection and development outcome. In this context, the identified physical form of the compound in the formulation is used as a guide for a risk–benefit assessment of the selected oral delivery technology. The potential of nano-suspensions for intravenous administration is unclear. In the case of oral administration, nano-suspensions are mainly used to improve the oral absorption characteristics of micronized formulations. The development of an in situ instantaneous solubilization method, based on stable, standardized liposomes with low toxicity, opens new avenues to solubilize poorly water-soluble compounds.

20 July 2011 in Photochemical & Photobiological Sciences
Verified
Journal Article
Closed access
PDF file
KYKewei Yang
Kewei Yang
BGBurkhard Gitter
Burkhard Gitter
RRRonny Rüger
Ronny Rüger
GWGerhard D. Wieland
Gerhard D. Wieland
MCMing Chen
Ming Chen
AFAlfred Fahr
Alfred Fahr
Photodynamic antimicrobial chemotherapy (PACT) and antimicrobial peptides (AMPs) are two promising strategies to combat the increasing prevalence of antibiotic-resistant bacteria. To take advantage of these two strategies, we integrated a novel antimicrobial peptide (WLBU2) and a potent generation II photosensitizer (temoporfin) into liposomes by preparing WLBU2-modified liposomes, aiming at bacteria targeted delivery of temoporfin for PACT. WLBU2 was successfully coupled to temoporfin-loaded liposomes using a functional phospholipid. The delivery of temoporfin to bacteria was confirmed by fluorescence microscopy and flow cytometry, thus demonstrating that more temoporfin was delivered to bacteria by WLBU2-modified liposomes than by unmodified liposomes. Consequently, the WLBU2-modified liposomes eradicated all methicillin-resistant Staphylococcus aureus (MRSA) and induced a 3.3 log10 reduction of Pseudomonas aeruginosa in the in vitro photodynamic inactivation test. These findings demonstrate that the use of AMP-modified liposomes is promising for bacteria-targeted delivery of photosensitizers and for improving the PACT efficiency against both gram-positive and gram-negative bacteria in the local infections.

12 July 2017 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
TSTereza Pereira de Souza
Tereza Pereira de Souza
GBGuilherme Volpe Bossa
Guilherme Volpe Bossa
Pasquale StanoPasquale Stano
Pasquale Stano
FSFrank Steiniger
Frank Steiniger
SMSylvio May
Sylvio May
AFAlfred Fahr
Alfred Fahr
Primitive cell models help to understand the role that compartmentalization plays in origin of life scenarios.